BOSTON, March 29, 2017 /PRNewswire/ -- Juniper
Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), a
women's health therapeutics company, today announced that it has
been recognized as one of greater Boston's 15 companies with the most diverse
boards, the GK15. The Company accepted the award at the Get
Konnected! 9th Anniversary professional networking event
on Tuesday, March 28 in Boston.
"Not only is our Board of Directors accomplished and highly
qualified in providing strategic guidance as we build a pipeline of
women's health therapeutics, the diversity of membership seen on
our Board is reflective of the real world," said Alicia Secor, Juniper's Chief Executive
Officer.
"Diversity is of crucial importance to our corporate culture,
and evidence supports that having a balanced and diverse Board is
associated with increased innovation, competitiveness and
sustainable growth, not to mention a more prosperous and inclusive
workplace."
In addition to honoring members of the GK15, the event included
a panel discussion and a fireside chat on gender and racially
diverse corporate boards.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics
that address unmet medical needs in women's health. The
Company is advancing a pipeline of proprietary product
candidates that leverage its differentiated intravaginal
ring technology and when appropriate the 505(b)(2) regulatory
pathway. Targeted product development investments are enabled
by Juniper's core operating business: the Crinone®
(progesterone gel) franchise and Juniper Pharma Services,
which provides high-end fee-for-service pharmaceutical development
and clinical trials manufacturing to clients. Please
visit www.juniperpharma.com for more information.
Juniper Pharmaceuticals™ is a trademark of Juniper
Pharmaceuticals, Inc., in the U.S. and EU.
Crinone® is a registered trademark of Merck
KGaA, Darmstadt, Germany, outside the U.S. and of Allergan plc
in the U.S.
To receive Juniper's press releases, SEC filings or calendar
alerts by email click here.
Follow us on LinkedIn
Forward Looking Statements
This press
release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of
1995, including statements relating to Juniper's ability
to leverage the 505(b)(2) pathway for its
product candidates and the expectation that Juniper's core
operating business will enable targeted product development
investments. Management believes that these forward-looking
statements are reasonable as and when made. However, such
forward-looking statements involve known and unknown risks,
uncertainties, and other factors that may cause actual results to
differ materially from those projected in the forward-looking
statements. For a discussion of certain risks and
uncertainties associated with Juniper Pharmaceuticals'
forward-looking statements, please review the
Company's reports filed with the SEC, including, but not
limited to, its Annual Report on Form 10-K. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date on which they are made.
These statements are based on management's current expectations
and Juniper Pharmaceuticals does not undertake any
responsibility to revise or update any forward-looking statements
contained herein, except as expressly required by
law.
Media Contact:
Amy Raskopf
Director, Corporate Communications, Juniper Pharmaceuticals,
Inc.
917-673-5775 / araskopf@juniperpharma.com
Investor Contact:
Laura Perry
Argot Partners
212-600-1902 / laura@argotpartners.com
Heather Savelle
Argot Partners
212-600-1902 / heather@argotpartners.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/juniper-pharmaceuticals-recognized-for-board-diversity-at-get-konnected-9th-anniversary-event-300430931.html
SOURCE Juniper Pharmaceuticals, Inc.